Join
Live feed
·
PRReleasevia Quantisnow
Zentalis Pharmaceuticals Inc. logo

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

ByQuantisnow·Wall Street's wire, on your screen.
ZNTL· Zentalis Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZNTL (Zentalis Pharmaceuticals Inc.) and more on Quantisnow.